You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will hold its Annual General Meeting ("AGM") in London later this morning.

Michael Gatenby, the Company's Chairman, will make the following statement:

Following a robust performance in 2013 when Alliance grew revenue to £45.5 million and increased pre-tax profits by 11% to £12.0 million, trading in the first four months of 2014 has been in line with expectations, with revenue of £15.2 million."

"Of particular note in the period to date has been the continued strong performance of the HydromolTM brand, which in the 12 months to April 2014 delivered revenue growth of 18%."

"Production volumes of Ashton and Parsons Infants' PowdersTM have increased significantly with the introduction of the new packaging machinery. We are now able, for the first time, to meet demand fully and are starting a promotional campaign behind the product. Revenue from Ashton and Parsons Infants' PowdersTM in the first four months of 2014 was £0.6 million, nearly 50% higher than the whole of 2013."

"We continue to search actively for acquisition opportunities and have available to us an acquisition bank facility of more than £20 million."

"As previously announced, I retire from Alliance immediately following this meeting and I'm proud to say that I leave the business in great shape. It has been a privilege to chair Alliance for the past 10 years, a period in which the Company has evolved into a profitable, cash generative business with a portfolio of more than 60 pharmaceutical products. I am confident that Alliance will continue on this growth path in future."

Andrew Smith, who assumes the Chairmanship immediately after the AGM, will make the following comments:

"On behalf of the Board, I would like to thank Michael very much for his strong leadership over the past decade. He has made a significant contribution to Alliance and we all wish him well for the future."

"We expect trading performance this year to be in line with our plans. We continue to work towards delivering further earnings enhancing acquisitions to outperform those plans."

FOR FURTHER INFORMATION:

Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer

Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar

Notes to editors:

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.